10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biocon has received the Drugs Controller General of India’s (DCGI) approval to market Alzumab (itolizumab) injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19. 13 July 2020
Swiss pharma giant Novartis has noted the publication of full results from the Phase III IRIDIUM study in The Lancet Respiratory Medicine, reminding physicians of the data supporting Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) in uncontrolled asthma. 10 July 2020
GlobalData expects the Hodgkin’s lymphoma market to grow from $1.2 billion in 2019 to $2.1 billion in 2029 across the eight major markets (8MM) at a moderate compound annual growth rate (CAGR) of 5.5%. 9 July 2020
Spanish company Grifols has begun European delivery of Tavlesse (fostamatinib) to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. 9 July 2020
US biotech Kymera Therapeutics has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. 9 July 2020
The National Institute for Health and Care Excellence (NICE) has recommended Adcetris (brentuximab vedotin) with cyclophosphamide, doxorubicin and prednisone (CHP), for untreated systemic anaplastic large cell lymphoma (sALCL) in adults, within a final appraisal document (FAD). 9 July 2020
Wisconsin, USA-based diagnostics company Promega is launching a new test for microsatellite instability (MSI) in the UK, which could help identify candidates for cancer immunotherapy. 9 July 2020
US cancer-focused biotech start-up Foghorn Therapeutics, formed in 2016, has announced it first major collaboration, signing a deal with US giant pharma Merck & Co. 9 July 2020
Canadian biotech firm Zymeworks saw its share gain 5% in after-hours trading yesterday, after announcing it has signed a new license deal with long-time partner, Merck & Co to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric and EFECT platforms. 9 July 2020
In a rare setback for immuno-oncology leader Keytruda (pembrolizumab), the US regulator on Wednesday rejected a bid for accelerated approval in liver cancer. 8 July 2020
Evive Biotech, a Shanghai-based biologics firm formerly known as Generon Biomed, has announced positive Phase III results for F-627 (efbemalenograstim alpha) to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients. 8 July 2020
Medicines regulator Health Canada has approved Sarclisa (isatuximab for injection) in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. 8 July 2020
Belgian drugmaker UCB and privately-held Swiss firm Ferring have signed a co-promotion agreement to commercialize the prefilled syringe formulation of Cimzia (certolizumab pegol) in the USA for the treatment of Crohn's disease (CD). 8 July 2020
Dutch biopharma Kiadis Pharma's shares kick off today, leaping 58% to 2.22 euros by early afternoon, after it announced an exclusive license deal for its previously undisclosed K-NK004 program with French pharma major Sanofi. 8 July 2020
Anglo-Swedish drugmaker AstraZeneca and US pharma giant Merck & Co have announced that Lynparza (olaparib) has been approved in the European Union (EU) for germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. 8 July 2020